Affiliation:
1. From the Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Abstract
Context.—
Breast pathology has many mimics and diagnostic pitfalls. Evaluation of malignant breast lesions, particularly in the biopsy setting, can be especially challenging, with diagnostic errors having significant management implications.
Objective.—
To discuss the pitfalls encountered when evaluating ductal carcinoma in situ and invasive breast carcinomas, providing histologic clues and guidance for appropriate use and interpretation of immunohistochemistry to aid in the correct diagnosis.
Data Sources.—
Data were obtained from review of pertinent literature of ductal carcinoma in situ and invasive breast carcinomas and from the experience of the authors as practicing breast pathologists.
Conclusions.—
Awareness of the pitfalls in diagnosing breast cancers is important when creating a differential diagnosis for each breast lesion evaluated. This review will cover some of these scenarios to aid in the diagnostic process.
Publisher
Archives of Pathology and Laboratory Medicine
Subject
Medical Laboratory Technology,General Medicine,Pathology and Forensic Medicine
Reference96 articles.
1. WHO Classification of Tumours Editorial Board.
Breast Tumours.
5th ed.
Lyon, France:
International Agency for Research on Cancer;
2019.
WHO Classification of Tumours; vol 2. https://tumourclassification.iarc.who.int/chapters/32. Accessed March 22, 2023.
2. Ductal carcinoma in situ: a proposal for a new classification;Holland;Semin Diagn Pathol,1994
3. Atypia in breast pathology: what pathologists need to know;Katayama;Pathology,2022
4. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast;Otterbach;Histopathology,2000
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献